Sage Therapeutics (NASDAQ:SAGE) Releases Earnings Results, Misses Expectations By $0.02 EPS

Sage Therapeutics (NASDAQ:SAGE) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02), Zacks reports. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Sage Therapeutics Price Performance

Sage Therapeutics stock traded down $0.07 during mid-day trading on Tuesday, reaching $7.19. 2,063,607 shares of the company were exchanged, compared to its average volume of 2,513,681. The company has a fifty day simple moving average of $6.28 and a 200-day simple moving average of $6.96. The firm has a market cap of $439.81 million, a PE ratio of -1.29 and a beta of 0.94. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $27.39.

Wall Street Analyst Weigh In

SAGE has been the subject of several research analyst reports. Truist Financial reduced their price target on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, October 30th. Stifel Nicolaus lowered their target price on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a report on Monday, December 16th. Oppenheimer cut their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Wednesday, October 30th. HC Wainwright reissued a “neutral” rating and issued a $14.00 target price on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $10.53.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.